By harnessing the body’s immune system to detect and destroy tumor cells, immune checkpoint inhibitors are rapidly ushering in a new era of precision medicine. Although immune checkpoint inhibitors have demonstrated durable clinical responses across several tumor types, these therapies are costly and may present toxic side effects.

Identify Patients More Likely to Respond to Immune Checkpoint Inhibitors with Biomarker Testing from Caris Molecular Intelligence:

Immunotherapy - PDL1, MSI, TML















1 Voena & Chiarle. Discov Med 2016; 21:125-33.

Comprehensive genomic and proteomic profiling with Caris Molecular Intelligence can help you make more informed therapy decisions when considering immune checkpoint inhibitors.